An effective and successful PneumoADIP could lead to millions of lives saved through earlier and faster access to vaccines.

An effective and successful PneumoADIP could lead to millions of lives saved through earlier and faster access to vaccines.

Mission & Approach

The mission of GAVI’s PneumoADIP is to improve child survival and health by accelerating the evaluation of and access to new, lifesaving pneumococcal vaccines for the world's children.

PneumoADIP is a dedicated team of experts and specialists based at the Johns Hopkins Bloomberg School of Public Health and is supported by a $30 million grant from the GAVI Alliance (GAVI). PneumoADIP aims to achieve its goals through partnerships with countries, donors, academia, international organizations, and industry. PneumoADIP coordinates its activities through a strategic alliance with the World Health Organization.

GAVI

The GAVI Alliance is a unique, multi-dimensional partnership of public and private sector resources with a single, shared focus: to improve child health in the poorest countries by extending the reach and quality of immunisation coverage within strengthened health services.

PneumoADIP APPROACH

PneumoADIP is organized around three main areas of activity.

PneumoADIP Approach

  • Establishing the value of vaccination by demonstrating the burden of meningitis and pneumonia caused by pneumococcal bacteria and demonstrating the value of prevention through vaccination.
  • Communicating effectively to key decision makers knowledge about disease burden and the value of vaccination.
  • Delivering the value of the vaccine by assuring that there is a predictable supply of quality vaccine at an affordable price, and an adequate system to deliver it to the children who need it, and the financing to sustain its use.
The Pneumococcal vaccines Accelerated Development and Introduction Plan is based
at Johns Hopkins Bloomberg School of Public Health and is funded by GAVI Alliance.